Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...

A novel blood test analyzing fragments of cell-free DNA showed robust diagnostic performance for colorectal cancer across clinical subgroups, offering a promising noninvasive screening method.

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...

The bulk of cfDNA research is founded upon DNA originating from cancer cells. Circulating tumor DNA (ctDNA) are nucleic biomarkers used to detect or monitor the advancement of cancer over time. These ...

As cost of sequencing continues to drop, the throughput and complexity of NGS assays have risen precipitously. At the same time, the types of samples being used for these assays have expanded as ...

In this interview, Dr. Anderson discusses the advantages of dd-cfDNA as a transplant monitoring tool and the regulatory and ...

Cell-free DNA (cfDNA) refers to fragments of DNA circulating in the bloodstream that originate from various sources, including dead or dying cells. In recent years, cfDNA has emerged as a promising ...

DELFI Diagnostics, Inc., developer of accessible blood-based, liquid biopsy tests that deliver a new way to enhance early cancer detection, announced that researchers from NYU Langone Health, in ...

Invasive diagnostic prenatal testing can provide the most comprehensive information about the genetic status of a fetus. Noninvasive prenatal screening methods, especially when using cell-free DNA ...

Next-generation sequencing (NGS) is an important component of first-line treatment selection for metastatic non–small-cell lung cancer (NSCLC) and is typically ordered by medical oncologists in the ...

Cell-free DNA (cfDNA) can act as a powerful biomarker for cancer research, from disease onset to therapy selection and minimal residual disease (MRD) measurement. Next-generation sequencing (NGS) has ...

Bold Capital and Bold Longevity Growth join strategic partners and previous investors as the platform moves towards commercialization for products in rheumatoid arthritis and cancer Aqtual is actively ...